Clinical Trials Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jan 14, 2017; 23(2): 306-317
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.306
Table 1 Characteristics of the modified intent-to-treat population
CharacteristicVacc. (n = 107)Ctr. (n = 115)P value
Demographics
Age, median (IQR)28.9 (23.1-37.1)29.3 (24.0-35.4)0.950
Male sex, n (%)86 (78.9)86 (74.1)0.400
Weight (kg), median (IQR)62.5 (56.0-70.0)63.0 (56.0-70.0)0.907
Genotype B, n (%)42/107 (39.3)39/115 (33.9)0.409
Week 0 laboratory results
ALT (IU/L), median (IQR)119.0 (94.0-167.5)136.0 (102.6-195.3)0.066
HBV DNA (log10 IU/mL), median (IQR)8.1 (7.7-8.3)8.1 (7.5-8.4)0.9532
HBeAg (COI), median (IQR)852.0 (223.5-1093.0)926.6 (508.5-1076.0)0.1972
HBsAg (IU/mL), median (IQR)10261.0 (3953.0-24089.0)8637.0 (2748.0-24436.0)0.7542
Week 12 laboratory results1
HBV DNA (log10 IU/mL), median (IQR)3.5 (2.6-4.5)3.4 (2.6-4.6)0.7542
HBeAg (COI), median (IQR)147.4 (15.6-650.0)45.9 (11.9-1011.0)0.6052
HBsAg (IU/mL) median (IQR)4072.0 (1608.0-8514.0)3023.5 (1167.0-11194.0)0.4602

  • Citation: Yang FQ, Rao GR, Wang GQ, Li YQ, Xie Y, Zhang ZQ, Deng CL, Mao Q, Li J, Zhao W, Wang MR, Han T, Chen SJ, Pan C, Tan DM, Shang J, Zhang MX, Zhang YX, Yang JM, Chen GM. Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. World J Gastroenterol 2017; 23(2): 306-317
  • URL: https://www.wjgnet.com/1007-9327/full/v23/i2/306.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v23.i2.306